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Is Ovarian Tissue Cryopreservation and
Transplantation Still Experimental? It Is
a Matter of Female Age and Type of
Cancer
TO THE EDITOR: We read with great interest the update of the
American Society of Clinical Oncology (ASCO) guideline on
fertility preservation in patients with cancer.1 The authors spent
much effort evaluating the current evidence on gonadotropin-
releasing hormone agonists, because new evidence has accumu-
lated since the ﬁrst update of the ASCO guideline published in
2013. However, cryopreservation and transplantation of ovarian
tissue were mentioned only brieﬂy, even though this technique has
also evolved considerably. The authors provided a general state-
ment that this technique is still experimental; however, current
evidence indicates that an overall classiﬁcation of this technique
should be replaced by a more sophisticated classiﬁcation, which
takes into consideration female age and type of cancer. For this
reason, we would like to deepen the discussion regarding this point;
in our opinion, it should be discussed much more intensively.
Deﬁning a technique as experimental or established is indeed
difﬁcult, because clear criteria are required. Provoost et al,2 rep-
resenting the Special Interest Group Ethics in Law and the Special
Interest Group Safety and Quality, both part of the European
Society of Human Reproduction and Embryology, proposed
a framework that distinguishes between experimental, innovative,
and established therapies. They suggested applying the criteria of
efﬁcacy, safety, procedure, and effectiveness to assess new tech-
nologies and treatments. If all these criteria are fulﬁlled, a tech-
nique can be classiﬁed as established. These criteria can also be
applied to classify ovarian tissue cryopreservation and trans-
plantation in children, adults with malignant disease with a high
risk of malignant cells in the ovaries (eg, those with leukemia), and
adults with malignant disease with a low risk of malignant cells in
the ovaries (eg, those with Hodgkin lymphoma or breast cancer).
Proof of principle (efﬁcacy) is still lacking in children, because
a live birth has only been achieved in one woman who had ovarian
tissue frozen in the peripubertal stage,3 but not in the prepubertal
stage. Accordingly, the effectiveness (effectiveness) is also still
unknown. Data on safety (safety) and technical performance
(procedure) in children are also poor. Therefore, cryopreservation
of ovarian tissue and transplantation must still be classiﬁed as
experimental in children. This is in line with the recommenda-
tions of the expert meeting of the European Society for Blood
Marrow Transplantation,4 which also classiﬁed this technique as
experimental.
In diseases such as leukemia, proof of principle (efﬁcacy) has
been demonstrated, because one child was born after trans-
plantation of tissue frozen from a woman with leukemia.5 In this
case, the tissue transplantation was performed after small samples
were grafted into immunodeﬁcient mice without developing
signs of leukemia. However, safety data (safety) are still poor. The
technique of cryopreservation is comparable between labora-
tories, but the technique of evaluating tissue before trans-
plantation is not (procedure). Accordingly, data on the overall
effectiveness (effectiveness) are also still poor, and therefore,
cryopreservation and transplantation of ovarian tissue in adults
with malignant disease and with a high risk of malignant cells in
the ovaries, such as in leukemia, must still be classiﬁed as ex-
perimental. This is in line with Dolmans et al,6 who described the
risk of ovarian metastasis as high in leukemia, neuroblastoma,
and Burkitt’s lymphoma.
In diseases with a low risk of ovarian metastasis,6 proof of
principle (efﬁcacy) has been demonstrated. Midterm safety data
have been provided,7 qualifying this technique as comparatively
safe (safety). The procedure of cryopreservation by slow freezing,
and evaluation of small tissue samples to exclude metastasis by
histology is comparable between laboratories (procedure).8 The
effectiveness has been proven, with a cumulative live birth and
ongoing pregnancy rate of 37.7% (effectiveness).7 In the largest
case series published so far, 16 deliveries were reported, six from
women with previous Hodgkin lymphoma and six from women
with previous breast cancer.9
In conclusion, we agree with the authors that this technique is
still experimental in children and in adults with malignant disease
with a high risk of malignant cells in the ovaries, such as in
leukemia. However, in those with a low risk of ovarian metastasis,
using the criteria of efﬁcacy, safety, procedure, and effectiveness, as
introduced by Provoost et al,2 this technique should be classiﬁed as
established and no longer experimental. This is also in line with the
German, Austrian, and Swiss guidelines on fertility preservation.10
We therefore strongly recommend categorizing this technique
according to female age and previous malignant disease, because an
inaccurate classiﬁcation has not only clinical implications re-
garding counseling but also political implications regarding
reimbursement.
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